Cover image of ARD podcast

ARD podcast

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Popular episodes

All episodes

The best episodes ranked using user listens.

Podcast cover

EULAR recommendations for the management of systemic lupus erythematosus

The highlights of the latest update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence, are discussed in this podcast.Read the full paper on the ARD website: https://ard.bmj.com/content/78/6/736.


12 Jul 2019

Rank #1

Podcast cover

Patient and doctor discordance may reduce chances of remission in rheumatoid and psoriatic arthritis

Discordance between patient's and physician's evaluation of disease activity may reduce likelihood of remission in rheumatoid arthritis and psoriatic arthritis. Dr Paul Studenic, Austria, is joined by Dr Brigitte Michelsen and Prof Tore Kvien, both from the department of Rheumatology at the Diakonhjemmet Hospital in Oslo, Norway, to discuss their study "Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study".Read the full details on the Annals of the Rheumatic Diseases website (http://ard.bmj.com/content/76/4/708), where you can also find the related Lay Summary (https://goo.gl/JBQbFc).


31 Jan 2018

Rank #2

Similar Podcasts

Podcast cover

Early inflammatory arthritis outcomes: what changed in the new millennium?

A study that compares the 10-year outcome (disease activity, disability, mortality) of two cohorts of patients with inflammatory polyarthritis recruited 10 years apart is discussed in this podcast. The results from the UK’s Norfolk Arthritis Register are shared by two of its co-authors from the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, School of Biological Sciences, Manchester Academic Health Science Centre: James Gwinnutt and Suzanne Verstappen (NIHR Manchester Biomedical Research Centre) in conversation with the social media advisor for ARD Meghna Jani.Read the full paper on the Annals of the Rheumatic Diseases website: https://ard.bmj.com/content/77/6/848.


10 Jul 2018

Rank #3

Podcast cover

Lupus and Hughes syndrome: EULAR recommendations for women's health and family planning

What are the recommendations of The European League Against Rheumatism (EULAR) for women's health and family planning after a diagnosis of lupus and/or antiphospholipid syndrome, also known as Hughes syndrome?Alessia Alunno (Rheumatology Unit, University of Perugia, Italy) talks to Laura Andreoli (Rheumatology and Clinical Immunology Unit, University of Brescia, Italy) about her paper recently published by ARD (ard.bmj.com)."EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome" is available here: http://ard.bmj.com/content/76/3/476.


20 Apr 2017

Rank #4

Most Popular Podcasts

Podcast cover

Capture Hi-C reveals novel drug targets in rheumatic diseases

The paper discussed in this podcast provides an approach, using Capture Hi-C data, to link genetic associations to potential causal genes and assess the potential of drug repurposing in three rheumatic diseases. This has the potential to identify genes which are functionally relevant and the target of existing therapies, which could provide new ways to treat patients, enhancing their quality of life and reducing the economic impact on healthcare providers. Read the full paper on the ARD website: https://ard.bmj.com/content/78/8/1127.


22 Aug 2019

Rank #5

Podcast cover

TULIP 1 - highlights from the ACR meeting

TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus ErythematosusIn this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.


10 Dec 2019

Rank #6

Podcast cover

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.


23 Jan 2020

Rank #7

Podcast cover

Three tips to get your manuscript published by ARD

Find out how to increase your chances of a successful submission in this very short podcast with Annals of the Rheumatic Diseases’s Associate Editor Francis Berenbaum. He is interviewed by the Social Media Advisor of the journal, Christophe Richez.Read more information for authors on the ARD website: https://ard.bmj.com/pages/authors/.Submit your manuscript here: https://mc.manuscriptcentral.com/ard.


29 Aug 2018

Rank #8

Podcast cover

TULIP 2: Efficacy and Safety of Anifrolumab in Patients

TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.


23 Dec 2019

Rank #9

Podcast cover

Similar performance of Humira and BI695501 biosimilar in active rheumatoid arthritis

The switch from Humira to BI 695501 had no impact on efficacy, safety and immunogenicity in patients with moderately to severely active rheumatoid arthritis, according to a study recently published by ARD and discussed in this short podcast.Professor Stanley Cohen (Metroplex Clinical Research Center, Dallas, Texas, USA) tells ARD’s social media advisor Elena Nikiphorou (clinical researcher at King’s College London, UK) how the conclusions should have an important economic impact, particularly in less favoured clinical settings in the world.Read the full paper on the Annals of the Rheumatic Diseases website: http://dx.doi.org/10.1136/annrheumdis-2017-212245.


28 Mar 2018

Rank #10